for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Affimed NV

AFMD.OQ

Latest Trade

3.06USD

Change

0.00(0.00%)

Volume

72,958

Today's Range

3.02

 - 

3.10

52 Week Range

2.53

 - 

5.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.06
Open
3.03
Volume
72,958
3M AVG Volume
11.54
Today's High
3.10
Today's Low
3.02
52 Week High
5.08
52 Week Low
2.53
Shares Out (MIL)
62.44
Market Cap (MIL)
182.80
Forward P/E
-5.83
Dividend (Yield %)
--

Latest Developments

More

Affimed NV Announces Submission Of Investigational New Drug Application To U.S. FDA To Initiate First-In-Human Phase 1/2A Study Of AFM24

Affimed NV Q2 Revenue EUR 4.0 Million Versus EUR 200,000

Affimed Announces Positive Clinical Data On AFM13 In CD30+ Lymphoma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Affimed NV

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry

Biotechnology & Drugs

Contact Info

Im Neuenheimer Feld 582

+49.6221.674360

https://www.affimed.com/

Executive Leadership

Thomas Hecht

Chairman of the Supervisory Board

Adi Hoess

Chief Executive Officer, Member of the Management Board

Florian Fischer

Chief Financial Officer, Member of the Management Board

Wolfgang Fischer

Chief Operating Officer, Member of the Management Board

Martin Treder

Chief Scientific Officer, Member of the Management Board

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.970

2017

-0.690

2018

-0.320

2019(E)

-0.336
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.31
Price To Book (MRQ)
5.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.69
LT Debt To Equity (MRQ)
1.73
Return on Investment (TTM)
-19.16
Return on Equity (TTM)
-14.81

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up